Editas Medicine, Inc. (EDIT) vs MapLight Therapeutics, Inc. (MPLT)

A side-by-side comparison of Editas Medicine, Inc. and MapLight Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

EDIT

Editas Medicine, Inc.

$430M

$2.81HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

MPLT

MapLight Therapeutics, Inc.

$412M

$9.72HealthcareDelayed quote: Oct 6, 2026, 3:05 PM EDT

Total return — EDIT vs MPLT

growth of $100 · dividends reinvested · last 1y

EDIT -23.6% (-23.6%/yr)MPLT -49.4% (-49.4%/yr)EDIT compounded faster over this window

EDIT MPLT

EDIT vs MPLT: by the numbers

•EDIT is the larger company ($430M vs $412M market cap).
•Both run net losses; MPLT's is the smaller (0.00% vs -157.32% net margin).

Metrics side by side

Valuation

Metric	EDIT	MPLT
P/S ratio	9.16	N/A
P/B ratio	4.09	1.18

Profitability

Metric	EDIT	MPLT
Gross margin	100.00%	0.00%
Operating margin	-245.15%	0.00%
Net margin	-157.32%	0.00%
ROE	-70.24%	-65.99%
ROIC	-48.61%	-69.35%

Growth (annualized)

Metric	EDIT	MPLT
Revenue CAGR (5Y)	-10.34%	N/A
Total return CAGR (5Y)	-40.76%	N/A

Go deeper

Full EDIT analysis Full MPLT analysis Interactive comparison tool

Dig into the metrics

Editas Medicine ROE MapLight Therapeutics ROE Editas Medicine operating margin MapLight Therapeutics operating margin Editas Medicine revenue growth MapLight Therapeutics revenue growth Editas Medicine free cash flow MapLight Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.